PRESCINTO-TECHNOLOGIES
22.11.2022 07:01:42 CET | Business Wire | Press release
Prescinto Technologies (“Prescinto”), a leading global clean energy asset performance management (APM) SaaS platform, and SunSolarWind IKE (“SunSolarWind”), a Thessaloniki-based wind and solar energy project developer with a rapidly growing portfolio of more than 100 projects across Greece, today announced a partnership in which Prescinto will apply its world-class AI-powered APM solution to monitor, analyze, optimize the performance of 70 MW of SunSolarWind’s solar assets. This alliance will streamline operations and maintenance for SunSolarWind and improve their solar asset generation by providing accurate, real-time data and actionable insights. The deal also marks Prescinto’s entry into the European market following the announcement of its recent entry into the North American market.
As one of the fastest-growing companies in Greece, SunSolarWind is a leader in renewable energy development and provides complete packages for the construction and management of wind and photovoltaic energy projects on behalf of its customers and partners. Using Prescinto’s proprietary AI-powered software, the company will have access to advanced monitoring technology and pre-trained data models to identify and categorize underperformance in real time. The platform will provide a single point of verification for SunSolarWind’s solar plant data, extracting up-to-the-minute insights and efficiently managing the field service team’s daily operations using Prescinto’s Monitor, Analyze, and Operate product modules. These solutions leverage data-driven intelligence to enable informed asset management and maximize the value of SunSolarWind clean energy assets.
In an increasingly competitive energy market, digital technology plays a critical role in optimizing operations and performance. SunSolarWind chose Prescinto as their digital transformation partner after a stringent evaluation of multiple other solutions. Additionally, Prescinto’s APM software is uniquely designed to efficiently adapt to the client's needs and is tailored to SunSolarWind’s specific requirements.
“Our team has worked closely with SunSolarWind to understand their bottlenecks and implement the appropriate solutions to enhance energy generation and streamline their operations,” said Puneet Singh Jaggi, founder and CEO of Prescinto. “As our first of many major partnerships to come in the European market, we are excited to be a part of SunSolarWind’s digital transformation journey and help them harness the full potential of their clean energy assets.”
“With our exponential growth in managed assets, the SunSolarWind team can now focus more on improving asset performance with a considerable reduction in time and effort,” says Konstantinos Fountas, Partner at SunSolarWind. “The advanced analytics in Prescinto’s platform helps to identify and plan remedial action and reduce equipment downtimes. For a company like ours, Prescinto’s solution, and their Computerized Maintenance Management System in particular, is a boon.”
With its expansion into the European market with its first Greece-based client, Prescinto is poised for further growth and progress toward its goal of being the asset management platform of choice for renewable energy projects, globally.
About Prescinto Technologies
Prescinto Technologies is a leading global clean energy asset performance management SaaS platform for solar, wind, and energy storage, purpose-built by industry experts to improve asset generation and accelerate the clean energy transition. Prescinto provides real-time insights, analytics, and automation support for optimizing renewable energy asset performance. With a veteran team of industry experts and a portfolio of over 13 GW across 14 countries, Prescinto is the trusted partner for global clients working toward the clean energy transition. For more info, visit www.prescinto.ai.
About SunSolarWind
Sun Solar Wind Ike is a rapidly growing company in the field of environmental energy applications, comprised of well-trained and certified staff. The company offers complete packages for the construction and management of photovoltaic systems and energy projects on behalf of either its customers or its partners – installers. With more than 70MWp of assets under management in Greece, SunSolarWind is among Greece's fastest-growing renewable energy companies. For more info, visit www.sunsolarwind.gr.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom